Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-senescence therapeutics - Cleara Biotech/Medical University of Graz/University Medical Center Groningen/University Medical Center Utrecht

Next Previous
Search
Drug Profile

Research programme: anti-senescence therapeutics - Cleara Biotech/Medical University of Graz/University Medical Center Groningen/University Medical Center Utrecht

Alternative Names: Anti-senescence molecules; FOXO4-D-retro inverso isoform; FOXO4-DRI; FOXO4-DRI peptide; FOXO4-p53 blocking peptides; FOXO4-p53 blocking therapeutics; FOXO4-p53 cell-penetrating peptides; Proxofim

Latest Information Update: 28 Feb 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cleara Biotech; Medical University of Graz; University Medical Center Groningen; University Medical Center Utrecht
  • Class Antineoplastics; Peptides
  • Mechanism of Action Apoptosis stimulants; FOXO4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Feb 2020 No recent reports of development identified for preclinical development in Cancer in Austria
  • 28 Feb 2020 No recent reports of development identified for preclinical development in Cancer in Netherlands
  • 06 Jul 2018 Cleara Biotech enters into partnerships with the University Medical Center in Utrecht, the University Medical Center in Groningen and the Medical University of Graz to discover and develop new therapeutics targeting senescent cells to treat age-related pathologies and therapy-resistant cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top